Evelien Roekevisch1, Phyllis Ira Spuls1, Denise Kuester2, Jacqueline Limpens1, Jochen Schmitt3. 1. Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands. 2. Centre for Evidence-based Healthcare, University Hospital Dresden, Dresden, Germany; Institute for Occupational and Social Medicine, Technical University Dresden, Dresden, Germany. 3. Centre for Evidence-based Healthcare, University Hospital Dresden, Dresden, Germany; Institute for Occupational and Social Medicine, Technical University Dresden, Dresden, Germany. Electronic address: jochen.schmitt@uniklinikum-dresden.de.
Abstract
BACKGROUND: Many patients with moderate-to-severe atopic dermatitis (AD) require systemic immunomodulating treatment to achieve adequate disease control. OBJECTIVE: We sought to systematically evaluate the efficacy and safety of systemic treatments for moderate-to-severe AD. METHODS: A systematic literature search was performed in MEDLINE, EMBASE, and CENTRAL (until June 2012). Randomized controlled trials (RCTs) evaluating systemic immunomodulating treatments for moderate-to-severe AD were included. Selection, data extraction, quality assessment, and generation of treatment recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach were performed independently by 2 reviewers. Efficacy outcomes were clinical signs, symptoms, quality of life, and the course of AD. Safety data were compared by calculating the weekly incidence rates (as percentages) for adverse events. RESULTS: Thirty-four RCTs with 12 different systemic treatments and totaling 1653 patients were included. Fourteen trials consistently indicate that cyclosporin A efficaciously improves clinical signs of AD. Cyclosporin A is recommended as first-line treatment for short-term use. A second-line treatment option is azathioprine, but efficacy is lower, and evidence is weaker. Methotrexate can be considered a third-line treatment option. Recommendations are impossible for mycophenolate, montelukast, intravenous immunoglobulins, and systemic glucocorticosteroids because of limited evidence. A meta-analysis was not performed because of a lack of standardization in outcome measures. CONCLUSION: Although 12 different interventions for moderate-to-severe AD have been studied in 34 RCTs, strong recommendations are only possible for the short-term use of cyclosporin A. Methodological limitations in the majority of trials prevent evidence-based conclusions. Large head-to-head trials evaluating long-term treatments are required.
BACKGROUND: Many patients with moderate-to-severe atopic dermatitis (AD) require systemic immunomodulating treatment to achieve adequate disease control. OBJECTIVE: We sought to systematically evaluate the efficacy and safety of systemic treatments for moderate-to-severe AD. METHODS: A systematic literature search was performed in MEDLINE, EMBASE, and CENTRAL (until June 2012). Randomized controlled trials (RCTs) evaluating systemic immunomodulating treatments for moderate-to-severe AD were included. Selection, data extraction, quality assessment, and generation of treatment recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach were performed independently by 2 reviewers. Efficacy outcomes were clinical signs, symptoms, quality of life, and the course of AD. Safety data were compared by calculating the weekly incidence rates (as percentages) for adverse events. RESULTS: Thirty-four RCTs with 12 different systemic treatments and totaling 1653 patients were included. Fourteen trials consistently indicate that cyclosporin A efficaciously improves clinical signs of AD. Cyclosporin A is recommended as first-line treatment for short-term use. A second-line treatment option is azathioprine, but efficacy is lower, and evidence is weaker. Methotrexate can be considered a third-line treatment option. Recommendations are impossible for mycophenolate, montelukast, intravenous immunoglobulins, and systemic glucocorticosteroids because of limited evidence. A meta-analysis was not performed because of a lack of standardization in outcome measures. CONCLUSION: Although 12 different interventions for moderate-to-severe AD have been studied in 34 RCTs, strong recommendations are only possible for the short-term use of cyclosporin A. Methodological limitations in the majority of trials prevent evidence-based conclusions. Large head-to-head trials evaluating long-term treatments are required.
Authors: E Haufe; S Abraham; A Heratizadeh; I Harder; A Zink; E Weisshaar; A Kleinheinz; R von Kiedrowski; M Worm; M Bell; A Wollenberg; K Neubert; P Staubach-Renz; M Hilgers; T Bieber; I Fell; B Homey; I Effendy; M Mempel; K Schäkel; S Beissert; S Weidinger; T Werfel; J Schmitt Journal: Hautarzt Date: 2018-10 Impact factor: 0.751
Authors: Eric Climent; Juan Francisco Martinez-Blanch; Laura Llobregat; Beatriz Ruzafa-Costas; Miguel Ángel Carrión-Gutiérrez; Ana Ramírez-Boscá; David Prieto-Merino; Salvador Genovés; Francisco M Codoñer; Daniel Ramón; Empar Chenoll; Vicente Navarro-López Journal: Microorganisms Date: 2021-04-15
Authors: Eric L Simpson; Emma Guttman-Yassky; David J Margolis; Steven R Feldman; Abrar Qureshi; Tissa Hata; Vera Mastey; Wenhui Wei; Laurent Eckert; Jingdong Chao; Renée J G Arnold; Tiffany Yu; Francis Vekeman; Mayte Suárez-Fariñas; Abhijit Gadkari Journal: JAMA Dermatol Date: 2018-08-01 Impact factor: 10.282
Authors: Vicente Navarro-López; Ana Ramírez-Boscá; Daniel Ramón-Vidal; Beatriz Ruzafa-Costas; Salvador Genovés-Martínez; Empar Chenoll-Cuadros; Miguel Carrión-Gutiérrez; José Horga de la Parte; David Prieto-Merino; Francisco M Codoñer-Cortés Journal: JAMA Dermatol Date: 2018-01-01 Impact factor: 10.282